(Q37842126)

24 August 2017

1 reference

title

Implementing prognostic and predictive biomarkers in CRC clinical trials (English)

1 reference

24 August 2017

0 references

Richard C. Turkington

object named as

Richard C Turkington

3

0 references

author name string

Sandra Van Schaeybroeck

1

1 reference

24 August 2017

Wendy L Allen

2

1 reference

24 August 2017

Patrick G Johnston

4

1 reference

24 August 2017

language of work or name

English

0 references

publication date

15 February 2011

1 reference

Nature Reviews Clinical Oncology

24 August 2017

1 reference

24 August 2017

8

1 reference

24 August 2017

222-232

1 reference

24 August 2017

4

1 reference

American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer

24 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Molecular predictors of survival after adjuvant chemotherapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Systematic review of microsatellite instability and colorectal cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Prognostic impact of gene expression-based classification for neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Reliable High-Throughput Genotyping and Loss-of-Heterozygosity Detection in Formalin-Fixed, Paraffin-Embedded Tumors Using Single Nucleotide Polymorphism Arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Metabolite profiling of human colon carcinoma--deregulation of TCA cycle and amino acid turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Clinical determinants of response to irinotecan-based therapy derived from cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Isolation of rare circulating tumour cells in cancer patients by microchip technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Analysis of circulating tumor DNA to confirm somatic KRAS mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Gene expression profiles of primary breast tumors maintained in distant metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Converting a breast cancer microarray signature into a high-throughput diagnostic test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Molecular staging for survival prediction of colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Approaches to working in high-dimensional data spaces: gene expression microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Roadmap for developing and validating therapeutically relevant genomic classifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Optimization of RNA extraction from formalin-fixed, paraffin-embedded lymphoid tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

RNA expression analysis from formalin fixed paraffin embedded tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Phases of biomarker development for early detection of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

The use of genomics in clinical trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Clinical trials for predictive medicine: new challenges and paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Use of genomic signatures in therapeutics development in oncology and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Clinical trial designs for prospective validation of biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Clinical trial designs for predictive marker validation in cancer treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Clinical trial designs for predictive biomarker validation: one size does not fit all.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

High-throughput oncogene mutation profiling in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

31 March 2020

Road map to metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Colon cancer prognosis prediction by gene expression profiling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Stage II colon cancer prognosis prediction by tumor gene expression profiling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

KRASMutation Signature in Colorectal Tumors Significantly Overlaps With the Cetuximab Response Signature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

DNA microarrays in clinical oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

On the efficiency of targeted clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

Evaluating the efficiency of targeted designs for randomized clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.15

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer

31 March 2020

1 reference

12 December 2020

Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin.

1 reference

12 December 2020

Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling.

1 reference

12 December 2020

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

1 reference

12 December 2020

CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer

1 reference

12 December 2020

10.1038/NRCLINONC.2011.15

Identifiers

DOI

1 reference

24 August 2017

1 reference